Funder
China National Key R&D Program
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference86 articles.
1. Li W, Zhao P, Chen L, Lai X, Shi G, Li L, et al. Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. Pharmacogenomics. 2020;21(2):101–10.
2. Deepak V, Howard LM, Charles E, Brian FG. The pharmacogenetics of coumarin therapy. Pharmacogenomics. 2005;6(5):503–13.
3. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical pharmacogenetics implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102:397–404.
4. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genom. 2006;16(2):101–10.
5. Liu J, Guan H, Zhou L, Cui Y, Cao W, Wang L. Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. Am J Transl Res. 2019;11(4):2507–15.